SentoClone International is a Swedish company developing SentoClone® technology as a global product. The concept behind the SentoClone® technology was developed at the Karolinska Institutet in Stockholm in 1999 with the first patent filed in 2002 and approved in 2007. The Company is owned by Jiangsu Sinorda Biomedicine Co. Ltd, China. Clinical development is performed in China together with the parent company.
SentoClone International holds an extensive global patent portfolio consisting of nine patent families and with patents granted within seven of these families.